Francesco Balestrieri Healthcare News

This is selected healthcare news for Francesco Balestrieri, which is filed under People. There are 4 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
4/29/2020 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
... been € 341.9 million, +9.4%. Dividend for 2019 € 1.00 per share (+8.7% vs 2018), of which € 0.48 already paid in November 2018. Number of Board members increased from eleven to twelve. New members appointed: Francesco Balestrieri, Giorgio De Palma, Guido Guidi and Piergiorgio Peluso (independent). Alfredo Altavilla appointed non executive Chairman ...
Globe Newswire
4/11/2019 Shionogi Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
OSAKA, Japan & AMSTERDAM- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced today that Shionogi concluded a distribution contract with Sandoz (Headquarters: Holzkirchen, Germany; CEO a.i: Francesco Balestrieri hereinafter “Sandoz”) for the sale of Rizmoic® (naldemedine) for the treatment of opioid-induced constipation (OIC ...
Business Wire
4/11/2019 How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently
... markets of Germany, the U.K. and the Netherlands. The drug won its U.S. nod in mid-2017 and just bagged official European approval in late February. In a Thursday statement, interim Sandoz chief Francesco Balestrieri framed the deal as “a significant step forward” for Sandoz's goal of “focusing increasingly on ...
FiercePharma
4/11/2019 How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently FiercePharma